Lee Hendricks

US Patent:

20160362488, Dec 15, 2016

Filed:

Apr 15, 2016

Appl. No.:

15/130263

Inventors:

- Bothell WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
Benjamin H. Dutzar - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Lee Hendricks - Bothell WA, US
Ethan W. Ojala - Snohomish WA, US
Pei Fan - Bothell WA, US
Jeffrey T.L. Smith - Bellevue WA, US
John A. Latham - Seattle WA, US
Charlie Karasek - Seattle WA, US
Jenny Mulligan - Lake Forest Park WA, US
Michelle Scalley-Kim - Seattle WA, US
Erica Stewart - Seattle WA, US
Vanessa Lisbeth Rubin - Seattle WA, US
Jens J. Billgren - Seattle WA, US

International Classification:

C07K 16/26
A61K 39/395
A61K 45/06
C07K 16/42

Abstract:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

US Patent:

20160304604, Oct 20, 2016

Filed:

Apr 15, 2016

Appl. No.:

15/130848

Inventors:

- Bothell WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
Benjamin H. Dutzar - Seattle WA, US
Daniel S. Allison - Lake Forest Park WA, US
Lee Hendricks - Bothell WA, US
Ethan W. Ojala - Snohomish WA, US
Pei Fan - Bothell WA, US
Jeffrey T.L. Smith - Bellevue WA, US
John A. Latham - Seattle WA, US
Charlie Karasek - Seattle WA, US
Jenny Mulligan - Lake Forest Park WA, US
Michelle Scalley-Kim - Seattle WA, US
Erica Stewart - Seattle WA, US
Vanessa Lisbeth Rubin - Seattle WA, US
Jens J. Billgren - Seattle WA, US

International Classification:

C07K 16/26
A61K 39/395
G01N 33/74
A61K 45/06

Abstract:

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific V, V, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.